Coagulation screen is more specific than the antcardiolipin antibody ELISA in defining a thrombotic subset of lupus patients

RONALD H W M DERKSEN,1 PAULA HASSELAAR,1 3 LAYA BLOKZIJL,1 3 FRITS H J GMELIG MEYLING,2 AND PHILIP G DE GROOT3

From the Departments of 1Internal Medicine (Division of Immunopathology), 2Clinical Immunology, and 3Hematology, University Hospital, Utrecht, The Netherlands

SUMMARY In 111 lupus patients we compared the potential of the IgG and IgM antcardiolipin antibody (ACA) enzyme linked immunosorbent assay (ELISA) and four different lupus anticoagulant (LAC) assays (partial thromboplastin time (PTT) of a 1:1 mixture of patient and control plasma with phospholipids from animal (PTT-st) or human brain (PTT-HB); PTT with dilutions of human brain phospholipids (PL dilution); and kaolin clotting time of mixtures of patient and control plasma (KCT)) to identify patients with thrombosis (26/111), fetal loss (19/46), and/or thrombocytopenia (11/106). The highest specificity for thrombosis (87%) was found with PTT-HB and PL dilution (sensitivity 65%, detection rate 61%); for fetal loss (93%) with PL dilution (sensitivity 47%; detection rate 82%), and for thrombocytopenia (83%) with KCT (sensitivity 82%; detection rate 36%). Compared with LAC assays, the sensitivity of ACA-ELISA was high (≥77%), but specificity (≤51%) and detection rate (≤52%) were low. So, a panel of three LAC assays (PTT-HB, PL dilution, and KCT) can identify lupus patients apparently at risk for thrombosis, fetal loss, and/or thrombocytopenia, whereas the ACA-ELISA is insufficiently specific.

Key words: lupus anticoagulant, systemic lupus erythematosus.

Several recent studies have shown that the presence of circulating antiphospholipid (anti-PL) antibodies, (notably lupus anticoagulant (LAC) or antcardiolipin antibodies (ACA), or both) in lupus patients is associated with a high prevalence of thrombosis, fetal loss, and/or thrombocytopenia.1-6 These antibodies are not specific for lupus as they have been described in otherwise healthy individuals, in association with certain drugs, and in patients with other autoimmune diseases, malignancies, or infections.4 6-8 Lupus anticoagulant has been defined as immunoglobulins that interfere with phospholipid dependent coagulation tests without inhibiting the activity of specific coagulation factors.9 Initially, tests for LAC focused on the effects of tissue thromboplastin dilution on the prothrombin time (PT) because previous investigators had found that the most specific effect of anti-PL antibodies was to block the activation of prothrombin by the prothrombin activator complex of factors Xa, V, calcium, and phospholipids.10 11 Subsequently it was shown that the (activated) partial thromboplastin time ((A)PTT) was more sensitive for LAC than the PT. A prolongation in the (A)PTT that is not correctable by 1:1 mixing with normal sera indicates the presence of LAC, provided that activities of individual coagulation factors are normal.9 11-13 Influences of the source14 15 and concentration9 10 16-19 of phospholipids on the results of phospholipid dependent coagulation assays have been recognised, however. Exner et al described characteristic patterns in the kaolin clotting time (KCT) assay when LAC positive and control plasmas were mixed at different ratios.20 This sensitive and specific LAC assay overcomes possible masking effects of exogenous phospholipids. Recently, Branch et al described an enzyme linked immunosorbent

Accepted for publication 2 October 1987.
Correspondence to Dr Ronald W M Derksen, Department of Internal Medicine, University Hospital, Catharijnesingel 101, 3511 GV Utrecht, The Netherlands.
Comparison of anticardiolipin antibody ELISA and lupus anticoagulant assays

assay (ELISA) with partial thromboplastin derived from human brain as an antigen, which enables detection of LAC in serum. At present there is uncertainty as to the best test for detecting LAC.

The association between LAC and biological false positive tests for syphilis on one hand and data indicating that cardiolipin is the principal antigen in these precipitation tests on the other, led to the introduction of solid phase immunoassays with cardiolipin as an antigen. Since the demonstration that raised ACA levels correlate both with LAC and with a history of thrombosis, fetal loss, and thrombocytopenia the ACA-ELISA is widely used. Studies on differences between various anti-PL antibody assays with respect to their potential for identifying patients with particular clinical features are rare.

Therefore, we compared in 111 patients with systemic lupus erythematosus (SLE) or lupus-like disease, the sensitivity, specificity, and detection rate of four different LAC assays, the ACA-ELISA, and combinations of these with respect to recognition of the subset of patients with thrombosis, fetal loss, and/or thrombocytopenia.

Patients and methods

Patients

One hundred and twenty-seven patients (97 with SLE according to American Rheumatism Association (ARA) criteria and 14 with signs and symptoms compatible with SLE but meeting less than four ARA criteria for the diagnosis (lupus-like disease), seen consecutively at the University Hospital, Utrecht, The Netherlands, were studied. There were 96 women and 15 men with a median age of 31 years (range 15–71) and median duration of disease of 7 years (range 0–1–29). Twenty-six patients had a history of thromboembolic manifestations. These included deep venous thrombosis of the legs (DVT; n=7); DVT and pulmonary emboli (n=3); DVT and cerebral infarction (n=4); DVT and central retinal artery thrombosis (n=1); DVT and thrombosis of digital arteries (n=1); DVT and transient ischaemic attacks (n=1); thrombophlebitis migrans (n=1); thrombophlebitis and central retinal artery thrombosis (n=1); pulmonary emboli (n=2); amaurosis fugax (n=1); amaurosis fugax and transient ischaemic attacks (n=1); thrombosis femoral artery, renal artery, and cerebral infarction (n=1); cerebral infarction (n=1); and central retinal artery thrombosis (n=1). In one patient DVT had occurred postpartum. None of the thromboembolic episodes had occurred in a postoperative period. Forty-six patients and 19/46 had a history of at least one pregnancy, and 19/46 had a history of fetal loss. The total number of pregnancies was 105. Of these, 66 ended with live births (in 38 women), 12 with first trimester abortion (in seven women), and 27 with second or third trimester fetal death (in 14 women). None of the patients had a bleeding tendency.

Samples

Blood samples for coagulation studies were obtained by venipuncture and collected into plastic tubes containing 3.8% trisodium citrate (0.129 mol/l) as the anticoagulant in a ratio of one part of anticoagulant to nine parts of blood. The samples were centrifuged at 4°C and 3000 g for 10 minutes to obtain platelet-poor plasma.

Blood samples for serum tests were obtained by venipuncture and collected into glass tubes without anticoagulants, at the same time as the platelet-poor plasma samples were drawn. The blood was allowed to clot at room temperature and then centrifuged at 175 g for 10 minutes to obtain serum.

Both platelet-poor plasma and serum were stored in small aliquots at −80°C until use. None of the patients was treated with heparin at the time of blood sampling.

Normal control blood samples were taken from healthy hospital workers with a median age of 29 years (range 23–46).

Assays for lupus anticoagulant

PTT system with partial thromboplastin derived from animal (monkey and rabbit) brain (PTT-st)

Test plasma (0.05 ml) was mixed with 0.05 ml control plasma in a glass tube (at 37°C). Immediately after mixing 0.1 ml commercial PTT reagent derived from monkey and rabbit brain (Boehringer, Mannheim, FRG) was added, mixed, and incubated for three minutes at 37°C. CaCl2, 25 mmol/l (0.1 ml) was then added and the clotting time was measured in duplicate (tilt tube method). A prolongation of the PTT by more than five seconds above that of pooled control plasma tested simultaneously indicated the presence of LAC. The normal value with pooled control plasma was 35 (5) s (mean (2SD) of 50 tests).

PTT system with partial thromboplastin derived from human brain (PTT-HB)

A partial thromboplastin was prepared in our laboratory according to the method of Hjort et al. using human crude brain extract. Test plasma (0.05 ml) was mixed with 0.05 ml control plasma in a glass tube at 37°C. Immediately after mixing 0.1 ml of the PTT reagent (stock solution diluted 1:100 in Michaelis acetate-veronal buffer solution) was added and incubated for eight minutes at 37°C. CaCl2 25 mmol/l (0.1 ml) was then added and the
clotting time measured in duplicate (tilt tube method). A prolongation of the PTT by more than 10 seconds above that of pooled control plasma tested simultaneously indicated the presence of LAC. The normal value with pooled control plasma was 55 (10) s (mean (2SD) of 50 tests).

**Phospholipid dilution test (PL dilution)**
The PTT of test plasma was measured as described above with different dilutions (Michaelis acetate-veronal buffer solution) of the stock solution derived from human brain (1:100; 1:175; 1:250). With pooled control plasma the PTT increased 5 (8) s (mean (2SD) of 50 tests) on dilution of the reagent from 1:100 to 1:250. The presence of more than 13 seconds increase with test plasma (all clotting times measured in duplicate) indicated the presence of LAC.

**Kaolin clotting time (KCT)**
Test and control plasma were mixed at 37°C at different ratios (0, 25, 50, 75, 100% test plasma) in plastic tubes. Immediately after mixing 0-1 ml of the mixtures was incubated with 0-05 ml kaolin (20 mg/ml Michaelis acetate-veronal buffer solution) for three minutes at 37°C. CaCl2 25 mmol/l (0-1 ml) was added and the time to clot formation accurately measured in duplicate on an automated coagulometer (KC10; Amelung GmbH, Lieme, West Germany). Results were expressed as a KCT index according to the formula described by Rosner et al.28

\[
\frac{(KCT: 1 \text{ mixture}) - (KCT \text{ control plasma})}{(KCT \text{ test plasma})} \times 100\% 
\]

In healthy controls (n=42) an index of 5 (12) (mean (2SD)) was calculated. Values above 17 indicated the presence of LAC.

**Antibodies to cardiolipin**
Twenty five microlitres of a solution of cardiolipin (Sigma, St Louis, Mo, USA; 48 µg/ml ethanol 70%) was added to 96 well polystyrene assay plates (Costar, Cambridge, MA, USA) and the cardiolipin coated on the surface by evaporation under nitrogen within six minutes. The uncoated area was blocked by addition of 150 µl of phosphate buffered saline (PBS) containing 10% fetal calf serum (FCS) for two hours at room temperature, washed three times with PBS, and then 50 µl of 1:32 and 1:256 dilutions (in PBS/10% FCS) of test serum was added in duplicate. The 1:32 dilution was chosen because in introductory experiments it provided the best discrimination between the average ‘background’ values of a cohort of 40 sera from apparently healthy volunteers and the values of 12 patients’ sera. A serum from a patient highly positive for both IgG-ACA and IgM-ACA, prediluted 1:4, served as a standard. This standard sample was diluted doubly from 1:32 to 1:1024 in PBS/10% FCS. Fifty microlitres of each of these six dilutions was added in duplicate to each plate to create a standard curve. Furthermore, 50 µl pooled control serum (diluted 1:32 and 1:256) was added to each plate as was 50 µl PBS/10% FCS to blank control wells.

After incubation for one hour at room temperature the plates were washed three times with PBS. Alkaline phosphatase conjugated antibodies (goat antihuman IgG or IgM alkaline phosphatase; Tago, Burlingame, CA, USA) were diluted in PBS/10% FCS (1:2000 for IgG; 1:1500 for IgM) and 50 µl was added to each well. After incubation for three hours at room temperature the plates were washed again with PBS. Then 100 µl substrate (0-6 mg p-nitrophenyl phosphate/ml diethanolamine buffer pH 9-8 (Sigma, St Louis, Mo, USA)) was added. After 15 minutes' incubation at room temperature the reaction was stopped by addition of 50 µl 2-4 M NaOH. Colour development was read at 405 nm in a Titertek multiscan photometer (Flow Laboratories, Finland). The absorbance at the 1:32 dilution of the standard sample was chosen arbitrarily as indicating the presence of 100 units of ACA. The absorbance read for the other samples was expressed as units using the computed standard curve. A positive result indicates a value in units more than 25 (71 apparently healthy volunteers tested on six different occasions) over the value obtained with pooled control serum. Positive results were graded according to criteria agreed upon at the international workshop on standardisation of the ACA assay in London: for IgG ACA low positive (mean (2SD) units<80); medium positive (80<units<185); high positive (units>185); for IgM ACA low positive (mean (2SD)<units<25); medium positive (25<units<200); high positive (units>200).

Intra-assay coefficients of variation, obtained by testing four dilutions of the standard sample (ACA levels of these dilutions covered the entire range of the assay) on the same plate 12 times, were found to be 6-4%, 7-1%, 3-4%, and 3-1% for IgG ACA and 10-6%, 9-0%, 4-4%, and 4-8% for IgM ACA. Interassay coefficients of variation expressed in units were calculated from 10 different assays during a period of two months. These were 14-8%, 9-5%, 10-4%, and 5-3% for IgG ACA and 14-6%, 10-2%, 8-6%, and 7-4% for IgM ACA.

**Platelet counts**
Blood platelets were counted in edetic acid-blood by the Coulter counter method.
Comparison of anticardiolipin antibody ELISA and lupus anticoagulant assays

Calculations

The \( \chi^2 \) test was used for statistical analysis. For evaluation the following definitions were used\(^{10} \): sensitivity—the probability that the test result will be positive when the patient has the particular symptom, or (true positive/(true positive + false negative))\( \times 100\% \); specificity—the probability that the result will be negative when the symptom is not present, or (true negative/(true negative + false positive))\( \times 100\% \); detection rate—the probability that the particular symptom will be present when the test result is positive, or (true positive/(true positive + false positive))\( \times 100\% \).

Results

Prevalence of Anti-PL Antibodies

In 47/111 patients at least one LAC assay was positive. Four positive LAC assays were found in 19 patients and three positive assays in seven patients (PL dilution negative (n=3), KCT negative (n=2), PTT-HB negative (n=1), PTT-st negative (n=1)). In five patients two LAC assays were positive (PTT-HB and PTT-st (n=2), PTT-HB and PL dilution (n=1), PTT-st and KCT (n=1), PTT-st and PL dilution (n=1)), and in 16 patients only one assay was positive (PTT-st (n=13), PL dilution (n=3)). Prevalences of a positive PTT-st, PTT-HB, PL dilution, and KCT were 38%, 25%, 25%, and 23% respectively.

Raised levels of IgG ACA were found in 63/111 patients. Most of these (51/63) were low positive; 8/63 were medium, and 4/63 high positive. Raised levels of IgM ACA were found in 63/111 patients. Of these, 47/63 were low positive; 14/63 medium, and 2/63 high positive.

Interassay Correlations

There was a significant relation between the results of the LAC assays (Table 1; \( p<0.005 \)). Raised levels of IgG ACA showed a significant relation with LAC detected in any assay (Table 1; \( p<0.05 \)). Raised IgG ACA levels were present in 29/42, 23/28, 25/28, and 22/25 patients with a positive PTT-st, PTT-HB, PL dilution or KCT respectively. Of the 12 sera that were medium or high positive for IgG ACA, seven were positive in all LAC assays; one was positive in all LAC assays except for PL dilution; two were positive for PL dilution only, and two were negative in all LAC assays. No significant relation was found between raised levels of IgM ACA and LAC; however, raised levels of IgM ACA and IgG ACA were significantly related (Table 1; \( p<0.005 \)).

Relation between Anti-PL Antibodies and Thrombosis

Twenty six patients had a history of thrombosis. Of these, 12 patients were positive in all LAC assays, five were positive in three LAC assays (negative only with PTT-st (n=1); negative only with PTT-HB (n=1); negative only with PL dilution (n=2); negative only with KCT (n=1); one was positive in two LAC assays (PTT-HB and PL dilution); and one was positive only with PL dilution. In seven patients with a history of thrombosis all LAC assays were negative, and six patients with a history of thrombosis were negative for IgG ACA. Of the latter patients, four were negative in all LAC assays and two had four positive LAC assays. Five patients with a history of thrombosis were negative for IgM ACA. Of these, two were negative in all LAC assays and three had four positive LAC assays. Six out of

Table 1  Interassay correlations

<table>
<thead>
<tr>
<th>Assay</th>
<th>PTT-HB</th>
<th>PL dilution</th>
<th>KCT</th>
<th>IgG ACA</th>
<th>IgM ACA</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTT-st</td>
<td>( \chi^2 ) value*&lt;br&gt;( p ) value</td>
<td>48-193&lt;br&gt;(&lt;5\times10^{-4})</td>
<td>31-250&lt;br&gt;(&lt;5\times10^{-4})</td>
<td>46-408&lt;br&gt;(&lt;5\times10^{-4})</td>
<td>4-159&lt;br&gt;(&lt;5\times10^{-2})</td>
</tr>
<tr>
<td>PTT-HB</td>
<td>( \chi^2 ) value*&lt;br&gt;( p ) value</td>
<td>64-314&lt;br&gt;(&lt;5\times10^{-4})</td>
<td>76-278&lt;br&gt;(&lt;5\times10^{-4})</td>
<td>9-832&lt;br&gt;(&lt;5\times10^{-3})</td>
<td>3-284 NS</td>
</tr>
<tr>
<td>PL dilution</td>
<td>( \chi^2 ) value*&lt;br&gt;( p ) value</td>
<td>59-096&lt;br&gt;(&lt;5\times10^{-4})</td>
<td>16-143&lt;br&gt;(&lt;5\times10^{-4})</td>
<td>12-833&lt;br&gt;(&lt;5\times10^{-4})</td>
<td>1-662 NS</td>
</tr>
<tr>
<td>KCT</td>
<td>( \chi^2 ) value*&lt;br&gt;( p ) value</td>
<td>10-163&lt;br&gt;(&lt;5\times10^{-3})</td>
<td>1-533 NS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*At 1 df.

Abbreviations: PTT-st=partial thromboplastin time with a commercial partial thromboplastin derived from animal brain; PTT-HB=partial thromboplastin time with a partial thromboplastin derived from human brain; PL=phospholipid reagent; KCT=kaolin clotting time; ACA=anticardiolipin antibodies.
twelve and 9/16 patients with medium or high levels of IgG ACA and IgM ACA respectively did not have a history of thrombosis. In all patients with a history of thrombosis levels of protein C, protein S, and AT III were normal.

We found a significant relation between the presence of anti-PL antibodies, detected by any of the assays, and a history of thrombosis (Table 2; \( \chi^2 \) value varying from 5.626 (IgG ACA; \( p<0.025 \)) to 29.618 (KCT; \( p<0.0005 \))). Table 2 shows the sensitivity, specificity, and detection rate of the anti-PL antibody assays for thrombosis. LAC detected with PTT-HB or PL dilution had the combination of a relatively high sensitivity (65%), specificity (87%), and detection rate (61%). For both IgG-ACA and IgM-ACA high sensitivities were found (\( \geq 77\% \)), but specificities (\( \leq 51\% \)) and detection rates (\( \leq 33\% \)) were low.

**Table 2**  
Anti-PL antibody assays and history of thrombosis

<table>
<thead>
<tr>
<th>Assay</th>
<th>( \chi^2 ) Value*</th>
<th>( p ) Value</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Detection rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTT-st</td>
<td>8.108</td>
<td>(&lt;5\times10^{-3})</td>
<td>61</td>
<td>69</td>
<td>38</td>
</tr>
<tr>
<td>PTT-HB</td>
<td>29.031</td>
<td>(&lt;5\times10^{-4})</td>
<td>65</td>
<td>87</td>
<td>61</td>
</tr>
<tr>
<td>PL dilution</td>
<td>29.031</td>
<td>(&lt;5\times10^{-4})</td>
<td>65</td>
<td>87</td>
<td>61</td>
</tr>
<tr>
<td>KCT</td>
<td>29.618</td>
<td>(&lt;5\times10^{-4})</td>
<td>61</td>
<td>69</td>
<td>64</td>
</tr>
<tr>
<td>IgG ACA</td>
<td>5.626</td>
<td>(&lt;2.5\times10^{-2})</td>
<td>77</td>
<td>49</td>
<td>32</td>
</tr>
<tr>
<td>IgM ACA</td>
<td>7.976</td>
<td>(&lt;5\times10^{-3})</td>
<td>81</td>
<td>51</td>
<td>33</td>
</tr>
</tbody>
</table>

*At 1 df.  
Abbreviations: see Table 1.

**Table 3**  
Anti-PL antibody assays and history of fetal loss*

<table>
<thead>
<tr>
<th>Assay</th>
<th>( \chi^2 ) Value†</th>
<th>( p ) Value</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Detection rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTT-st</td>
<td>6.377</td>
<td>(&lt;2.5\times10^{-2})</td>
<td>63</td>
<td>74</td>
<td>63</td>
</tr>
<tr>
<td>PTT-HB</td>
<td>11.529</td>
<td>(&lt;1\times10^{-3})</td>
<td>58</td>
<td>89</td>
<td>79</td>
</tr>
<tr>
<td>PL dilution</td>
<td>9.787</td>
<td>(&lt;5\times10^{-3})</td>
<td>47</td>
<td>93</td>
<td>82</td>
</tr>
<tr>
<td>KCT</td>
<td>9.483</td>
<td>(&lt;5\times10^{-3})</td>
<td>53</td>
<td>89</td>
<td>77</td>
</tr>
<tr>
<td>IgG ACA</td>
<td>4.166</td>
<td>(&lt;5\times10^{-2})</td>
<td>84</td>
<td>44</td>
<td>52</td>
</tr>
<tr>
<td>IgM ACA</td>
<td>2.690</td>
<td>NS</td>
<td>79</td>
<td>44</td>
<td>50</td>
</tr>
</tbody>
</table>

*Forty six women with a history of pregnancy were evaluated.  
†At 1 df.  
Abbreviations: see Table 1.
with a history of both thrombosis and pregnancy had experienced fetal loss. The relation between these parameters was significant ($\chi^2$=9.483; $p<0.005$).

**RELATION BETWEEN ANTI-PL ANTIBODIES AND PRESENCE OF THROMBOCYTOPENIA**

Of the 106 patients studied, 11 had platelet counts below $150 \times 10^9$/l and four of these below $100 \times 10^9$/l. Five of the 11 patients with thrombocytopenia were positive in all anti-PL antibody assays, three were positive in all assays except for IgM ACA, and one patient was negative for LAC with PTT-st and positive in all other anti-PL assays. Two patients were negative in all anti-PL assays except for IgM ACA.

A significant relation was found between presence of thrombocytopenia and a positive LAC assay. $\chi^2$ varied from 5.999 with PTT-st ($p<0.025$) to 23.094 with the KCT ($p<0.0005$) (Table 4). LAC detected with the KCT had the highest specificity (83%); the detection rate of all assays was relatively low ($\leq 36\%$) (Table 4).

**RELATION BETWEEN THE PRESENCE OF THROMBOCYTOPENIA AND HISTORY OF THROMBOSIS**

Eight of the 11 patients with thrombocytopenia had a history of thrombosis, whereas a history of fetal loss was present in five of the seven patients with thrombocytopenia who had been pregnant. The presence of thrombocytopenia was significantly related to a history of thrombosis ($\chi^2$=17.579; $p<0.0005$), but not to a history of fetal loss ($\chi^2$=3.616).

**Discussion**

Current data indicate that both LAC and raised ACA levels are markers of a subset of lupus patients with a high prevalence of thrombosis, fetal loss, and thrombocytopenia.\(^1\)\(^{-}\)\(^6\) Whereas ACA are uniformly detected by solid phase immunoassays, there are many coagulation assays to detect anti-PL antibodies.\(^9\)\(^{-}\)\(^{20}\)\(^{22}\) Both the presence of deficiencies or inhibitors of specific coagulation factors and heparin should be distinguished from LAC as the cause of an abnormal assay result.\(^12\)\(^{-}\)\(^{20}\)\(^{22}\) If control and test plasma are mixed before assessment of the clotting time and an incubation period is avoided, as we did in our assays, this usually prevents interference of coagulation factor deficiencies and inhibitors respectively in LAC assays. The presence of strong inhibitors of coagulation factors, however, cannot be excluded, unless specifically looked for in LAC positive samples.\(^16\)\(^\)\(^{19}\)\(^{22}\) Such strong inhibitors, however, are rare and are usually associated with a bleeding tendency. Heparin can be neutralised with protamine sulphate in case heparin is present in the test sample.\(^19\)

With the PTT-st and PTT-HB assays we found a prevalence of LAC of 38% and 25% respectively. This difference is probably caused by differences in PL composition between the thromboplastins used.\(^14\)\(^\)\(^15\) The prevalence of LAC defined with PL dilution and KCT was 25% and 23% respectively. The prevalence (57%) we found for increased ACA serum concentrations is comparable with the 54% recently described in an unselected Swedish population of patients with SLE.\(^31\)

Our data confirm the presence of a close relation between results of individual LAC assays, and between the presence of LAC and raised levels of IgG ACA. In our series most LAC positive patients (69–89%, depending on the assay used) had raised levels of IgG ACA. In other reports\(^1\)\(^6\)\(^25\)\(^{32}\)\(^{-}\)\(^{34}\) this percentage varies between 76%\(^{34}\) and 100%.\(^32\) In accordance with Branch et al\(^33\) we found that there are clearly patients with discordant results for LAC and ACA assays. Depending on the LAC assay used we found that 11–31% of LAC positive patients were IgG ACA negative and that 54–65% of IgG ACA positive patients did not have LAC. Also, two

---

**Table 4  Anti-PL antibody assays and presence of thrombocytopenia (platelets <150×10^9/l)**

<table>
<thead>
<tr>
<th>Assay</th>
<th>$\chi^2$ Value *</th>
<th>p Value</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Detection rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTT-st</td>
<td>5.999</td>
<td>$&lt;2.5 \times 10^{-2}$</td>
<td>73</td>
<td>61</td>
<td>16</td>
</tr>
<tr>
<td>PTT-HB</td>
<td>20.527</td>
<td>$&lt;5 \times 10^{-4}$</td>
<td>82</td>
<td>81</td>
<td>33</td>
</tr>
<tr>
<td>PL dilution</td>
<td>20.527</td>
<td>$&lt;5 \times 10^{-4}$</td>
<td>82</td>
<td>81</td>
<td>33</td>
</tr>
<tr>
<td>KCT</td>
<td>23.094</td>
<td>$&lt;5 \times 10^{-4}$</td>
<td>82</td>
<td>83</td>
<td>36</td>
</tr>
<tr>
<td>IgG ACA</td>
<td>2.750</td>
<td>NS</td>
<td>82</td>
<td>44</td>
<td>15</td>
</tr>
<tr>
<td>IgM ACA</td>
<td>1.299</td>
<td>NS</td>
<td>73</td>
<td>45</td>
<td>13</td>
</tr>
</tbody>
</table>

*At 1 df.

Abbreviations: see Table 1.
out of 12 patients with medium or high IgG ACA levels were negative in all LAC assays. In other reports, the prevalence of a negative ACA assay in the presence of LAC varies between 0% and 42%, and of a negative LAC assay in the presence of IgG ACA between 17% and 73%. These data clearly indicate that equation of LAC and ACA should be prevented. If the fact that cardiolipin is only a minor constituent of the platelet membrane is taken into account, our finding of a strong correlation between LAC and the presence of thrombocytopenia and the absence of such a relation between IgG ACA and thrombocytopenia supports suggestions made by others that other negatively charged phospholipids (e.g., phosphatidylserine) constitute the reactive epitope for antibodies detected with a coagulation assay. In addition, the discordant effect of prednisone on LAC and on IgG ACA levels, which was previously described by us, supports this notion.

The absence of a relation between LAC and raised IgM ACA levels is in accordance with early and recent reports, which indicate that LAC is almost always caused by IgG and only occasionally by IgM class antibodies directed against negatively charged phospholipids.

A comparison of the sensitivity, specificity, and detection rate of the anti-PL antibody assays with respect to a history of thrombosis or fetal loss and the presence of thrombocytopenia showed that three of the LAC assays (PTT-HB, PL dilution, and the KCT) are superior to PTT-st or the ACA-ELISA. Higher specificity of LAC compared with ACA was also found by Petri et al., who used the Russell viper venom time to define LAC. In contrast, in a prospective study, Lockshin et al found ACA superior to LAC for prediction of fetal distress or death. By raising the cut off levels in the ACA-ELISA we could increase the specificity of this assay to 93%, but just like others we found this was always accompanied by a severe drop in sensitivity (≤30%).

Harris et al reported, for ACA levels more than 5–6 SD above the mean control level, values for sensitivity, specificity, and detection rate that are comparable with those found by us with any of three LAC assays. Unfortunately, these authors did not include the LAC assay in their analysis. The discrepancies between our studies with respect to the value of the ACA assay are difficult to explain. Sera exchanged between our laboratories were concordantly classified as negative, low, medium, or high positive for ACA. The total number (111) of patients, their age, and the number of patients with a history of fetal loss (19) are about the same in both studies, but the number of patients with a history of thrombosis is quite different (26 vs 60).

Although the availability of laboratory tests that have a sensitivity of about 50–75% and a specificity of about 80–85% towards thrombosis and fetal loss can indeed be regarded as useful for the characterization of a particular subset of patients, prospective studies will have to confirm and extend these findings before adequate therapeutic regimens can be advocated for patients with anti-PL antibodies. This is strengthened both by data from a recent prospective study on 50 pregnant patients with SLE, which showed that with raised ACA levels or increased (A)PTT values, respectively 25% or 50% of the pregnancies resulted in live births, and by the follow up of two of our patients who have had recorded LAC (both with PTT-HB and PL dilution methods) for at least 10 years but never had thrombosis.

In conclusion, our data show that a panel of LAC assays (PTT-HB; PL dilution; KCT) is useful for the detection of lupus patients with thrombosis, fetal loss, and/or thrombocytopenia, whereas the ACA assay is insufficiently specific for this purpose.

This work was supported by a grant (85 CR 46) from the Nederlandse Vereniging voor Reumabestrijding.

References

Comparison of anticardiolipin antibody ELISA and lupus anticoagulant assays  


15 Kelsey P R, Stevenson K J, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time—

16 Thiagarajan P, Pengo V, Shapiro S S. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagu-

17 Triplett D A, Brandt J T, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue


19 Alving B M, Baldwin P E, Richards R L, Jackson B J. The dilute phospholipid APTT: a sensitive assay for verification of

20 Exner T, Rickard K A, Kronenberg H. A sensitive test


23 Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-


27 Hjort P, Rapaport S I, Owren P A. A simple specific one-stage

and quantitative evaluation of lupus circulating anticoagulant

29 Harris E N, Gharavi A E, Patel S P, Hughes G R V. Evaluation of
the anticardiolipin antibody test: report of an international
215–22.

30 Griner P F, Mayewsk R J, Mushlin A I, et al. Selection and


32 Harris E N, Chan J K H, Asherson R A, Aber V R, Gharavi A E, Hughes G R V. Thrombosis, recurrent fetal loss, and
thrombocytopenia. Predictive value of the anticardiolipin

33 Branch D W, Rote N S, Dostal D A, Scott J R. Association of

34 Lockshin M D, Quamar T, Druzin M, Goei S. Antibody to
cardiolipin, lupus anticoagulant, and fetal death. J Rheumatol
1987; 14: 259–62.

35 Derksen R H W M, Biesma D, Bouma B N, Gmelig Meyling F H J, Kater L. Discordant effects of prednisone on antici-

36 Yin E T, Gaston L W. Purification and kinetic studies on a
circulating anticoagulant in a suspected case of lupus erythema-


38 Lockshin M D, Druzin M L, Goei S, et al. Antibody to
cardiolipin as a predictor of fetal distress or death in pregnant
Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.

R H Derksen, P Hasselaar, L Blokzijl, F H Gmelig Meyling and P G De Groot

doi: 10.1136/ard.47.5.364

Updated information and services can be found at:

[http://ard.bmj.com/content/47/5/364](http://ard.bmj.com/content/47/5/364)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)